.png)
Super high pure, pluripotentable and scalable MSC
While MSC (mesenchymal stem cell) has recently emerged as a new modality which has great potential to tackle many difficult diseases, it still faces difficult challenges; namely 1) expandability, 2) differentiation ability and 3) migration ability in the body. To conquer all of such challenges, our company’s extremely purified MSC, “REC” (Rapidly Expanding Cells), is ready for production. Our founder, Dr. Yumi Matsuzaki, established a unique method to select the very best MSC from human bone marrow and to proliferate to the ultimate level. Nothing is genetically modified. Just selected and purified. “REC” can expand from a single cell to 1 x 10^12 cells within 12 weeks by showing clearer differentiation abilities, for example to make bones. During our preclinical mouse test, “REC” showed clog-free migration in the body without indicating any trace of pulmonary embolism.
Business Information:
Name of the company:
PuREC Co., Ltd.
Year of establishment:
2016
Location of the headquarters:
Shimane, JP
Other key location(s):
Tokyo, JP
Spinout from:
Shimane University Medical School
Year of establishment:
2016
PuREC is a spinout from Shimane University with patented technologies to produce purified MSC, or mesenchymal stem cells. PuREC's REC is coming from Rapidly Expanding Cells enabling the synthesis of 10^12 ordered pure cells within 12 weeks without requiring complicated methodologies such as gene-modification.
Company website:
High pure MSC for specific disease target - bone metabolic diseases
This base-technology can be used for many types of applications including cell therapy field for orphan diseases. PuREC has been running collaborative research and joint projects with Hokkaido and Shimane Universities and Japanese corporates. PuREC is prepared for the first in-human trial for hypophosphatasia (a rare bone-formation deficiency disease for new-born babies), ready for its clinical trial in 2021. Also two other orthopaedic applications (e.g. disc herniation and joint diseases) will be in IND phase within a few years. Those three disease targets are in ongoing pipeline with challenging total $23.5bn world-wide market.
Using the same platform technology, PuREC is looking for business partners to invest on the following disease types:
Crohn's disease
GvHD (Graft-versus-host disease)
Spinal cord injury
Stroke
Brain injury
Other joint diseases
Technology validation:
Technology readiness level (TRL)
6
CEO message:
Value if IP (patents)
PuREC is currently preparing the IND for hypophosphatasia (a rare bone-formation deficiency disease for new born babies) with our uniquely purified MSC (mesenchymal stem cell). Two other orthopedic disease are expected to file IND in a few years. We are confident that our specially purified MSC, called “REC”, can be applied also for other disease areas as well.
As our first-in-human trial is expected to start in 2021, we seek for license partners and investors to solidify furhter development; esipecially in Europe and U.S.
No data
Current business stage:
Series A stage
Next investment required:
Target exit style:
IPO in Japan
Clinical study level (if relevant):
Hide Takahashi
Technical literatures:
Biospire's roles:
- Business globalisation, increase touchpoints to global academia, investor introduction, etc.